© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to December
oral PI3K_-selective kinase inhibitor prodrug
preclinical candidate for breast cancer
from mining of prior PI3K inh., SBDD, and opt.
J. Med. Chem., Dec. 24, 2020
Pfizer, San Diego, CA
Pfizer oral PI3ka-selective kinase inhibitor prodrug
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.